Roughly a third of research peptide orders that originate in the United States are bound for Canadian institutions or independent researchers. The cross-border layer is the single most operationally difficult part of the supply chain — and in 2026 it’s gotten harder, not easier. This is a practical walkthrough of how Canadian fulfillment actually works for research peptides, what the failure modes look like, and how to evaluate a supplier’s cross-border posture.
The two failure modes
From the researcher’s perspective, two things can go wrong on a US-to-Canada shipment:
1. Customs detention
A package is held at the border for inspection or because the declared contents trigger a flag. Canadian Border Services Agency (CBSA) detentions usually resolve one of three ways: release after additional documentation, return-to-sender, or destruction. From the tracking history, the package shows “release pending” or stalls at “Customs Processing” for an extended period.
Baseline rate, across multiple supplier sources in 2026: somewhere around 10% of US-to-Canada research peptide shipments experience some form of customs intervention. The rate varies by destination province, declared value, packaging style, and carrier — but a single-digit-percentage failure rate is normal even for suppliers doing this competently.
2. Lost-in-carrier
Less common but operationally identical from the researcher’s perspective: the carrier loses the package after customs clearance, or marks it delivered when it wasn’t, or returns it without explanation. The supplier’s response policy to lost-in-carrier should be the same as to customs detention — reship without litigation.
What good supplier policy looks like
The defining policy is the answer to a single question: “If this shipment doesn’t arrive, what happens?”
Good answer: “We reship at no cost. Send us your address; we’ll route the replacement through a different forwarder.” For each Canadian shipment, the batch lot number on the vial label can be cross-checked against the published Janoshik HPLC certificate of analysis — verify before reconstitution.
Bad answer: “Send us evidence the package was intercepted. We’ll review.”
The reason the first answer is right and the second is wrong: it’s structurally impossible for a customer to “prove” customs interception in a way a supplier can verify independently. CBSA doesn’t send proactive notifications to the recipient in many cases — the tracking just stops updating. Asking the customer to produce evidence is in practice asking them to do nothing and accept the loss. A supplier that builds reships into the operating cost of the business is one that has done the math: 10% intercept rate at ~$30 cost-per-reship is a 3% effective premium on Canadian orders, which is absorbable. A supplier asking customers to fight customs is offloading that cost back to the buyer.
Bastion Peptides ships from US fulfillment with a stated “free reship if customs seizes” policy. The replacement uses different routing — typically a different forwarder, sometimes a different carrier path — to avoid hitting the same flag pattern that triggered the first interception.
The packaging variables that actually affect intercept rate
Within the constraints of safely shipping lyophilized peptides, several packaging choices affect customs friction:
- Declared value. A shipment declared at $400 receives more scrutiny than one declared at $30. Suppliers that declare values for research-use-only material at reasonable supply-cost levels generally see fewer flags than suppliers that declare them at retail.
- Package size and weight. A small bubble mailer routes through customs differently than a flat-rate box. Smaller is generally less flagged.
- HS code on the customs declaration. The Harmonized System code determines whether the shipment routes to general inspection or to pharmaceutical inspection. Suppliers experienced with cross-border use codes that route to general inspection — research chemicals or similar — rather than to drug review.
- Carrier. USPS-to-Canada Post hands off through a specific customs queue; FedEx and UPS handle their own customs brokerage with different inspection profiles. Different carriers have different effective intercept rates by category.
- Cold-chain markings. “Refrigerate on arrival” stickers and ice-pack cooler shipping draw additional attention. For compounds that genuinely need cold chain (reconstituted peptides, some lyophilized compounds), there’s no avoiding it; for compounds that don’t, eliminating the marking reduces flags.
Most of these are decisions the supplier makes for you. The researcher’s job is to choose a supplier that has clearly thought through these variables — not to micromanage individual shipments.
What to do when your shipment stalls
A practical sequence when tracking hasn’t updated in 7+ days for a US-to-Canada shipment:
- Wait 48 more hours. Customs queues are not real-time; “Customs Processing” can sit static for two weeks and then resolve. Don’t escalate prematurely.
- Check your CBSA notifications. If CBSA has formally requested information about the shipment, you’ll have a letter or email from them. If you have nothing from CBSA, the shipment is in the queue, not actively reviewed.
- Email support@yoursupplier. Request a reship if 14+ days have elapsed without movement past Customs Processing. Most reputable suppliers will reship without further documentation.
- Do not contact CBSA directly about the shipment. This is generally counterproductive and can escalate a passive review to an active one. Let the carrier and supplier handle customs interface.
- Update your address if you’ve moved. Reship goes to the address you confirm — don’t assume it goes to the original address.
What changes by destination province
Customs intercept rates aren’t uniform across Canada. Anecdotally from 2025-2026 supplier data:
- Ontario destinations (Toronto / GTA, Ottawa) — slightly above the national average, possibly because of port-of-entry volume.
- Western Canada (BC, Alberta, Saskatchewan) — close to the national average, with Vancouver intercept rates marginally higher than Calgary or Edmonton.
- Quebec destinations (Montreal, Quebec City) — close to the national average, but customs correspondence comes in French by default, which is operationally easier for francophone recipients.
- Atlantic Canada (Halifax, Moncton, St. John’s) — generally below the national average for intercept rate but with longer delivery times.
- Northern destinations (Yukon, NWT, Nunavut) — too low volume to characterize statistically.
For researchers in higher-intercept regions, the practical mitigation is to ensure your supplier’s reship policy is strong, not to switch suppliers. Geographic intercept variance is real but not large enough to change which supplier you use; a supplier with a clean reship policy absorbs the variance for you.
Payment from Canadian buyers
Payment from Canadian researchers used to be a separate friction — Canadian Visa or Mastercard charges to US-domiciled research suppliers historically failed at the issuer. Bastion now uses a specialised PayPal/card processor that handles cross-border research-compound transactions cleanly, which has largely resolved the payment-layer rejection problem.
Putting it together
The Canadian cross-border layer is not a problem with a clever solution — it’s a problem suppliers have to absorb. The right supplier:
- Publishes a clear reship policy (and stands behind it without litigation)
- Uses packaging and declaration choices that route shipments through general inspection rather than pharmaceutical review
- Has a payment processor configured for Canadian cards and PayPal so buyers don’t get rejected at the payment layer
- Communicates clearly when shipments stall — sets expectations, doesn’t disappear
Bastion Peptides is built around exactly this set: free reship if customs seizes, PayPal and card checkout, US fulfillment with packaging that’s been iterated for cross-border. The catalog is open for Canadian researchers without payment-side friction or surprise denials.
For research use only. Bastion Peptides supplies compounds intended for laboratory and in-vitro research. Not for human or veterinary consumption.